TACE联合PD-1抑制剂和TKI多模式治疗 肝细胞癌的临床效果分析
Analysis of the Clinical Efficacy of TACE Combined with PD-1 Inhibitors and/or TKI Multimodal Treatment of Hepatocellular Carcinoma
DOI: 10.12677/acm.2026.163866, PDF,    科研立项经费支持
作者: 色 汗*, 王 琳：内蒙古科技大学包头医学院研究生院，内蒙古 包头；内蒙古自治区人民医院/内蒙古大学人民医院肿瘤内科，内蒙古 呼和浩特；斯日古楞：呼和浩特市第一医院泌尿外科，内蒙古 呼和浩特；净 净, 桂晓梦：内蒙古自治区人民医院/内蒙古大学人民医院肿瘤内科，内蒙古 呼和浩特；内蒙古医科大学内蒙古临床医学院，内蒙古 呼和浩特；李皓静, 杨 宏#：内蒙古自治区人民医院/内蒙古大学人民医院肿瘤内科，内蒙古 呼和浩特
关键词: TACE；PD-1抑制剂；TKI多模式治疗；肝细胞癌；系统治疗；TACE； PD-1 Inhibitor； TKI Treatment； Hepatocellular Carcinoma； Systemic Treatment
摘要: 目的：分析TACE联合PD-1抑制剂和TKI多模式治疗肝细胞癌的临床效果，以期进一步提升HCC治疗有效率。方法：分析于我院进行治疗的肝细胞癌患者基本资料，选择50例进行研究，经数字随机法等分为各25例的研究组和对照组，对照组实施TACE联合PD-1抑制剂治疗，研究组实施TACE联合联合PD-1和TKI多模式治疗，对比治疗效果、肿瘤标志水平、肝功能指标以及不良反应发生率。结果：研究组患者DCR为92.00%，高于对照组的68.00%；转化切除率为88.00%，高于对照组的60.00%(P < 0.05)，而ORR与对照组无明显差异(P > 0.05)；研究组患者无进展生存期以及中位总生存期均显著高于对照组(P < 0.05)；治疗后研究组AFP、CA19-9、CEA、DCP等肿瘤标志物水平均显著低于对照组(P < 0.05)。治疗后研究组AST、ALT、TBil等肝功能指标均显著低于对照组(P < 0.05)；研究组患者治疗期间不良反应发生率为48.00%，与对照组的36.00%无明显差异(P > 0.05)。结论：TACE联合联合PD-1和TKI多模式治疗能够提升治疗有效性，改善患者身体指标，且不会造成不良反应发生率的增加，具有应用参考价值。
Abstract: Objective: Analyze the clinical effect of TACE combined with PD-1 inhibitors and/or TKI multimodal treatment of hepatocellular carcinoma (HCC), in order to further improve the effectiveness of HCC treatment. Methods: Analyzing the basic information of HCC patients who were treated in our hospital, and 50 cases were selected for study. They were divided into a study group and a control group of 25 cases each by digital randomization. The control group was treated with TACE combined with PD-1 inhibitors, and the research group was treated with TACE combined with PD-1 and TKI multi-modal treatment. The treatment effects, tumor marker levels, liver function indicators, and incidence of adverse reactions were compared. Results: The DCR of patients in the study group was 92.00%, which was higher than 68.00% in the control group, the transformation resection rate was 88.00%, which was higher than 60.00% in the control group(P < 0.05), while the ORR was not significantly different from that in the control group (P > 0.05); the progression-free survival and median overall survival of patients in the study group were significantly higher than those in the control group (P < 0.05); after treatment, the levels of tumor markers such as AFP, CA19-9, CEA, and DCP in the study group were significantly lower than those in the control group (P < 0.05); after treatment, liver function indicators such as AST, ALT, and TBil in the study group were significantly lower than those in the control group (P < 0.05); the incidence of adverse reactions in the study group during treatment was 48.00%, which was not significantly different from 36.00% in the control group (P > 0.05). Conclusion: TACE combined with PD-1 and TKI multimodal therapy can improve the effectiveness of HCC treatment and improve patients’ physical indicators without causing an increase in the incidence of adverse reactions, which has application reference value.
文章引用：色汗, 斯日古楞, 净净, 王琳, 桂晓梦, 李皓静, 杨宏. TACE联合PD-1抑制剂和TKI多模式治疗 肝细胞癌的临床效果分析[J]. 临床医学进展, 2026, 16(3): 939-946. https://doi.org/10.12677/acm.2026.163866

参考文献

[1] 路会林, 常祖宽, 娄雪磊. TACE联合PD-1抑制剂和(或) TKI多模式治疗肝细胞癌的临床效果及影响因素分析[J]. 实用癌症杂志, 2025, 40(10): 1682-1687.
[2] 阚璇. 肝动脉灌注化疗联合抗PD-1免疫疗法和酪氨酸激酶抑制剂治疗不可切除肝细胞癌效果[J]. 吉林医学, 2025, 46(9): 2201-2205.
[3] 张锋涛. 肝动脉灌注化疗联合抗PD-1单克隆抗体治疗肝细胞癌伴微血管侵犯患者安全性和有效性[J]. 介入放射学杂志, 2025, 34(6): 624-630.
[4] 郎旭, 刘博宇. TACE联合仑伐替尼及PD-1抑制剂治疗伴门静脉癌栓的肝细胞癌患者的疗效及安全性[J]. 中国临床药理学与治疗学, 2025, 30(5): 648-656.
[5] 唐置鸿, 袁度, 许少伟, 等. 初始不可切除肝细胞癌行血管介入联合TKI及PD-1抑制剂转化治疗后序贯肝切除术的安全性和有效性研究[J]. 海军军医大学学报, 2025, 46(2): 206-214.
[6] 蒋家云, 张辉, 张诗育, 等. TACE联合仑伐替尼及PD-1单抗治疗中晚期肝细胞癌的疗效及安全性分析[J]. 陆军军医大学学报, 2024, 46(22): 2529-2538.
[7] 周晓燕, 陈勇, 王媛媛, 等. TACE与TKI联合或不联合PD-1抑制剂治疗晚期肝细胞癌有效性与安全性的Meta分析[J]. 中国肿瘤生物治疗杂志, 2024, 31(11): 1136-1145.
[8] 徐静, 丁哲, 徐颖. 基于Tumor Fisher CTC检测探讨PD-1/PD-L1免疫抑制剂治疗肝细胞癌的效果[J]. 肝脏, 2024, 29(10): 1184-1188.
[9] 周晓燕, 陈勇, 王媛媛, 王晓贤, 刘洁, 林雨虹. TACE与TKI联合或不联合PD-1抑制剂治疗晚期肝细胞癌有效性与安全性的Meta分析[J]. 中国肿瘤生物治疗杂志, 2024, 31(11): 1136-1145.
[10] 汪景洲, 王宇鹏, 刘航成, 等. 卡瑞利珠单抗联合TACE对伴微血管侵犯肝细胞癌患者肿瘤标志物、血管生成因子和血清PD-1、PD-L1的影响[J]. 现代生物医学进展, 2024, 24(9): 1678-1681.
[11] 刘迪, 姚维杰, 吴向阳, 等. PD-1抑制药联合经肝动脉化疗栓塞术与酪氨酸激酶抑制药治疗不可切除肝细胞癌患者的临床研究[J]. 中国临床药理学杂志, 2023, 39(22): 3223-3227.
[12] 吕浩鹏, 康宇航, 刘青松, 等. 仑伐替尼 + 经肝动脉化疗栓塞 + PD-1单抗(LEN-TAP)转化治疗对中晚期肝细胞癌患者剩余肝脏体积的影响[J]. 中国普外基础与临床杂志, 2024, 31(1): 16-23.
[13] 吴翠婷, 周雪辉, 张婉馨. 基于生物学信息分析筛选晚期肝细胞癌患者接受PD-1抑制剂治疗后糖酵解相关基因差异表达并构建生存获益模型与验证[J]. 现代检验医学杂志, 2023, 38(5): 34-39.
[14] 彭秋菊, 戴涛, 谢贵波, 等. 不可切除肝细胞癌的经肝动脉化疗栓塞术联合靶向药物或程序性死亡受体1及其配体单抗治疗进展[J]. 临床肝胆病杂志, 2023, 39(7): 1740-1746.
[15] 古善智, 黄满平, 谭玉林, 等. 多纳非尼片联合抗PD-1单抗和经导管动脉化疗栓塞术治疗不可手术切除的肝细胞癌的临床研究[J]. 临床肿瘤学杂志, 2023, 28(7): 609-614.
[16] Yuan, Y., He, W., Yang, Z., Qiu, J., Huang, Z., Shi, Y., et al. (2023) TACE-HAIC Combined with Targeted Therapy and Immunotherapy versus TACE Alone for Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Propensity Score Matching Study. International Journal of Surgery, 109, 1222-1230. [Google Scholar] [CrossRef] [PubMed]
[17] Lin, K.Y., Lin, Z.W., Chen, Q.J., Luo, L.P., et al. (2023) Perioperative Safety, Oncologic Outcome, and Risk Factors of Salvage Liver Resection for Initially Unresectable Hepatocellular Carcinoma Converted by Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor and Anti-Pd-1 Antibody: A Retrospective Multicenter Study of 83 Patients. Hepatology International, 17, 1477-1489. [Google Scholar] [CrossRef] [PubMed]

为你推荐